Drug Information

Drug General Information
Drug ID
D0P5AE
Former ID
DIB014086
Drug Name
Ecallantide
Synonyms
FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea
Drug Type
Small molecular drug
Indication Retinal venous occlusion [ICD10:H34.8] Approved [522774], [541991]
Company
Dyax Corp
Formula
C305H442N88O91S8
PubChem Compound ID
44152182
PubChem Substance ID
135263125, 164339270
Target and Pathway
Target(s) Kallikrein Target Info Inhibitor [536771]
Plasma kallikrein Target Info Inhibitor [536771]
KEGG Pathway Complement and coagulation cascades
NetPath Pathway AndrogenReceptor Signaling Pathway
PANTHER Pathway Blood coagulation
PathWhiz Pathway Coagulation
Reactome Intrinsic Pathway of Fibrin Clot Formation
Activation of Matrix Metalloproteinases
WikiPathways Complement and Coagulation Cascades
Human Complement System
Blood Clotting Cascade
Formation of Fibrin Clot (Clotting Cascade)
References
Ref 522774ClinicalTrials.gov (NCT00969293) Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion. U.S. National Institutes of Health.
Ref 541991(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6955).
Ref 536771Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.